ROR2 CAR T Study Targets Adverse Risk AML Stem Cells

Company Shenzhen University and collaborators Event Type Peer-Reviewed Preclinical Publication (Cancer Gene Therapy) Modality CAR-T cell therapy (anti-ROR2) Asset Anti-ROR2 CAR T construct (preclinical) Target ROR2 Disease Area Adverse-risk acute myeloid leukemia Summary An online-first peer-reviewed Cancer Gene Therapy paper identifies surface ROR2 on a…